Cost-effectiveness of Paxlovid in reducing severe COVID-19 and mortality in China.

ABSTRACT:

Objectives

To assess the cost-effectiveness of Paxlovid in reducing severe COVID-19 and its associated morality, and to investigate the affordable price of Paxlovid in China.

Materials and methods

Using a Markov model, two interventions by Paxlovid prescription (with and without prescription) were compared in terms of COVID-19-related clinical outcomes and economic loss. COVID-related costs were collected from the societal perspective. Effectiveness data were obtained from literature. The primary outcomes were total social cost, disability adjusted life-years (DALYs) and net monetary benefit (NMB). Scenario analyses were performed to investigate the affordable price of Paxlovid in China. Deterministic sensitivity analyses (DSA) and probabilistic sensitivity analysis (PSA) we

SUBMITTER: Zhang W 

PROVIDER: S-EPMC10315619 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature